Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Skin Diseases and Disorders

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

Antifungal Agents

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corneal tomography detection of elevated ectasia risk in atopic dermatitis patients with no prior ophthalmologic diagnosis.

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia·2026

Same author

Do Prophylactic Antibiotics Decrease Risk of Infection in Closed Percutaneous Pinning of Pediatric Hand Fractures?

Journal of pediatric orthopedics·2026

Same author

Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>.

Oncology letters·2026

Same author

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation.

Allergologie select·2026

Same author

Why physicians underuse patient-reported outcomes in atopic dermatitis and chronic urticaria - Insights from the UCARE/ADCARE PROMUSE study.

The World Allergy Organization journal·2026

Same author

What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation.

Annals of hematology·2026

Search research articles

Related Experiment Video

Updated: May 18, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Interventions for mycosis fungoides.

Tobias Weberschock¹, Reinhard Strametz, Maria Lorenz

¹Evidence-based Medicine Frankfurt, Institute for General Practice, Goethe University, Frankfurt, Germany. Tobias.Weberschock@kgu.de.

The Cochrane Database of Systematic Reviews

|September 14, 2012

Summary

This review found limited evidence for mycosis fungoides treatments due to low-quality studies. Topical therapies are recommended first for early-stage cutaneous T-cell lymphoma, with caution for systemic treatments due to adverse effects.

Related Experiment Videos

Last Updated: May 18, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Area of Science:

Dermatology
Oncology
Clinical Trials

Background:

Mycosis fungoides is the most common cutaneous T-cell lymphoma, a chronic skin malignancy.
Various therapies exist, offering temporary clinical remission for patients.

Purpose of the Study:

To evaluate the efficacy and safety of interventions for mycosis fungoides across all disease stages.
To synthesize evidence from randomized controlled trials (RCTs) on mycosis fungoides treatments.

Main Methods:

Conducted a systematic literature search of multiple databases up to January 2011.
Included 14 RCTs involving 675 participants, focusing on Alibert-Bazin-type mycosis fungoides.
Assessed study eligibility, quality, and extracted data on primary (quality of life, safety) and secondary outcomes.

Main Results:

Included studies had low methodological quality, small sample sizes, and high dropout rates.
Investigated treatments included topical agents, light therapies, oral medications, and systemic agents.
Clearance rates varied widely (0-83%); no significant differences in clearance were found for IFN-α plus PUVA vs. PUVA alone. No studies showed significant improvements in disease-free intervals, relapse, or survival.

Conclusions:

Comparative safety and efficacy of mycosis fungoides interventions cannot be established due to study heterogeneity and quality limitations.
Topical and skin-directed treatments are recommended for early stages due to potential serious adverse effects of systemic therapies.
Larger, high-quality studies with defined endpoints focusing on safety, quality of life, and remission duration are needed.